primary peritoneal cancer

Showing 1 - 25 of 88

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Beijing, Beijing, China
    Lingying Wu
Aug 22, 2023

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Houston (Paclitaxel, Carboplatin, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 13, 2023

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,

Recruiting
  • High Grade Serous Ovarian Cancer
  • +2 more
  • Upifitimab rilsodotin
  • Placebo
  • Phoenix, Arizona
  • +40 more
Jan 25, 2023

Homologous Recombination Inquiry Through Ovarian Malignancy

Completed
  • Ovarian Cancer
  • +2 more
    • Niigata city, Niigata Prefecture, Japan
      Niigata University Graduate School of Medical and Dental Science
    Jan 19, 2023

    Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

    Active, not recruiting
    • Epithelial Ovarian Cancer
    • +2 more
    • New Haven, Connecticut
    • +1 more
    Jan 11, 2023

    Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)

    Recruiting
    • Mucinous Ovarian Cancer
    • +2 more
    • Bevacizumab + modified FOLFIRINOX
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Dec 25, 2022

    Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer Trial in Canada, United States (DSP-7888 Dosing

    Completed
    • Renal Cell Carcinoma (RCC)
    • +5 more
    • DSP-7888 Dosing Emulsion
    • +2 more
    • Tucson, Arizona
    • +18 more
    Dec 6, 2022

    Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +

    Completed
    • Epithelial Ovarian Cancer
    • +2 more
    • NY-ESO-1 OLP4
    • +2 more
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    High-Grade Ovarian Cancer Terms of Homologous Recombination

    Not yet recruiting
    • Ovarian Cancer
    • +2 more
    • Standard of care
    • (no location specified)
    Oct 7, 2022

    Solid Tumor, Colorectal Cancer, Cholangiocarcinoma Trial in France, United States (TRK-950, Irinotecan, Leucovorin)

    Recruiting
    • Solid Tumor
    • +11 more
    • TRK-950
    • +14 more
    • Scottsdale, Arizona
    • +13 more
    Oct 2, 2022

    Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

    Completed
    • Melanoma
    • +25 more
    • Scottsdale, Arizona
    • +10 more
    Sep 27, 2022

    Rucaparib in Rucaparib Access Program in Spain - A GEICO Study

    Completed
    • Epithelial Ovarian Cancer
    • +2 more
    • Almería, Andalucía, Spain
    • +22 more
    Sep 22, 2022

    Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

    Recruiting
    • Platinum-resistant Ovarian Cancer
    • +6 more
    • olvimulogene nanivacirepvec
    • +3 more
    • Orlando, Florida
      AdventHealth Cancer Institute
    Sep 1, 2022

    Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer Trial in Houston (Paclitaxel/Bev (control), Paclitaxel/Bev + ZA

    Recruiting
    • Epithelial Ovarian
    • +2 more
    • Paclitaxel/Bev (control)
    • Paclitaxel/Bev + ZA (experimental)
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Canada, United States (Nemvaleukin

    Recruiting
    • Platinum-resistant Ovarian Cancer
    • +2 more
    • Nemvaleukin and Pembrolizumab Combination
    • +6 more
    • Ventura, California
    • +7 more
    Aug 5, 2022

    High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

    Not yet recruiting
    • High Grade Ovarian Cancer
    • +2 more
    • (no location specified)
    Jul 11, 2022

    Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer Trial in Birmingham (mirvetuximab soravtansine (MIRV; IMGN853))

    Recruiting
    • Ovarian Cancer
    • +2 more
    • mirvetuximab soravtansine (MIRV; IMGN853)
    • Birmingham, Alabama
      University of Alabama at Birmingham Womens & Infants Center
    Jun 30, 2022

    Assess Safety and Effectiveness of Zirabev in Domestic Various

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +7 more
    • (no location specified)
    Jun 30, 2022

    Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Toronto (Niraparib, Dostarlimab, Bevacizumab)

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    May 2, 2022